What Jubilant Ingrevia does

Jubilant Ingrevia Limited is a publicly listed Indian specialty chemicals and CDMO company headquartered in Noida, serving pharmaceutical, nutrition, agrochemical, consumer, semiconductor, and industrial customers across 63 countries via a portfolio of 130+ products built on 35+ chemistry platforms. The company's revenue is generated through direct B2B enterprise sales, multi-year contracts, and quote-based pricing across five streams: Specialty Chemicals (with leadership positions in Pyridine and Vitamin B3/Niacinamide), CDMO services anchored by a ₹2,500 crore/$300M long-term agrochemical contract, Nutrition Ingredients (including the Remidex acquisition), Chemical Intermediates (covering 280+ APIs), and emerging Semiconductor Chemicals. Manufacturing runs across six primary Indian locations (Gajraula, Bharuch, Nira, Savli, Ambernath, Bengaluru) totaling 1,000+ acres and 50+ plants, with regulatory approvals including US FDA, WHO GMP, FSSC 22000, and FAMI-QS; R&D is delivered through three centers (Greater Noida, Gajraula, Bharuch) staffed by 150 scientists including 30 PhDs, with the Greater Noida site being DSIR-recognized.

Underlying the operations is an AI/digital infrastructure consisting of digital twins across 27 facilities, AI-based retrosynthesis tools, flow-chemistry-plus-AI development, predictive supply-chain analytics, and AI-led procurement auctions; the Bharuch facility's WEF Lighthouse Factory recognition validates the depth of this deployment. The company's strategic Pinnacle345 program targets a 3x revenue and 4x EBITDA expansion by FY30, supported by approximately ₹2,000 crore of capex deployed over the prior two years, a 50+ project R&D pipeline, and a multi-channel GTM combining direct enterprise sales, industry-event presence (DCAT, CPHI, EPCA, Chemspec), and global storage hubs in Europe and South Korea. FY 2026 financials were revenue of ₹4,388 crore (+5% YoY), EBITDA of ₹607 crore, and PAT of ₹278 crore (+11% YoY), with the margins mix shifting toward higher-value specialty and CDMO streams.

Name

Jubilant Ingrevia

Legal name

Jubilant Ingrevia Limited

Website

https://jubilantingrevia.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Jubilant Ingrevia is a publicly listed Indian specialty chemicals and CDMO company serving pharmaceutical, nutrition, agrochemical, semiconductor, consumer, and industrial customers across 63 countries, with a 130+ product portfolio spanning 35+ chemistry platforms and leadership positions in Pyridine and Vitamin B3/Niacinamide.

Ownership category

akta.pro rank

Product category

Specialty Chemicals & CDMO

NAICS

Chemical Manufacturing (325), Pharmaceutical and Medicine Manufacturing (32541), Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Medicinal and Botanical Manufacturing (325411)

SIC

Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833), Chemicals & Allied Products (2800), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Warehousing, Blending & Distribution for Agrochemicals (bulk handling, IBC/drum management) (AFABAIAL), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Specialty chemicals manufacturing
• Pharmaceutical intermediates
• Agrochemical intermediates
• Contract development manufacturing
• Nutrition ingredients

Headquarters

HQ city

Noida

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Specialty Chemicals: High-margin specialty chemicals segment with 21% EBITDA growth, including Pyridine and Vitamin B3 (Niacinamide) leadership positions. This is the company's fastest-growing segment as it pivots from cyclical commodity chemicals.
2. CDMO (Contract Development and Manufacturing Organization): Custom manufacturing services for pharmaceutical and agrochemical customers. Includes a $300 million (approximately ₹2,500 crore) long-term agrochemical CDMO contract commencing March 2026, with 16 confirmed molecules and peak revenue potential of around ₹3,500 crore.
3. Nutrition Ingredients: Human nutrition business including vitamins, premixes, and mineral complexes. Completed acquisition of Remidex to accelerate growth. 21% revenue growth in nutrition segment.
4. Chemical Intermediates: Bulk and fine intermediates for 280+ APIs for pharmaceutical customers, and high-performance intermediates and actives for agrochemical customers.
5. Semiconductor Chemicals: High-purity specialty chemicals for advanced chip manufacturing - emerging growth vertical.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Jubilant Ingrevia manufactures and supplies specialty chemicals and provides Contract Development and Manufacturing Organization (CDMO) services for pharmaceutical, agrochemical, nutrition, consumer, semiconductor, and industrial customers. Its portfolio spans 130+ products across 35+ chemistry platforms, including pyridine derivatives, Vitamin B3 (Niacinamide), bio-based chemicals, intermediates for 280+ APIs, agrochemical actives, nutrition premixes and mineral complexes, antimicrobials, cosmetics/flavour ingredients, and high-purity semiconductor chemicals. Manufacturing is conducted at six India-based facilities (Gajraula, Bharuch, Nira, Savli, Ambernath, Bengaluru) supported by three R&D centres.

Product overview

Jubilant Ingrevia is a leading global solutions provider of Specialty Chemicals and CDMO services with a broad portfolio of 130+ products across 35+ chemistry platforms. The company operates a unified offerings model combining specialty chemicals manufacturing (including Pyridine derivatives, Vitamin B3/Niacinamide, and bio-based chemicals) with integrated CDMO services for pharmaceutical and agrochemical customers. The product portfolio spans pharmaceutical intermediates (280+ APIs), agrochemical actives, nutrition ingredients (vitamins, premixes), industrial antimicrobials, cosmetics/flavour ingredients, and high-purity semiconductor chemicals. Manufacturing footprint includes six primary locations in India (Gajraula, Bharuch, Nira, Savli, Ambernath, Bengaluru) with R&D capabilities across three centers supporting the full spectrum from custom synthesis to commercial scale production.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Chemicals Customised specialty chemicals (130+ products across 35+ chemistry platforms) for pharmaceutical, agrochemical, consumer, industrial, and semiconductor customers; manufactured at six India-based facilities with backward integration.
• CDMO (Contract Development and Manufacturing Organization) Services End-to-end CDMO services for pharmaceutical and agrochemical customers including custom synthesis, process development, and manufacturing from pilot to commercial scale, supported by US FDA / WHO GMP approved Bharuch facility.
• Pharmaceutical Intermediates Bulk and fine intermediates for 280+ Active Pharmaceutical Ingredients (APIs) enabling cost-effective healthcare solutions for pharmaceutical customers.
• Agrochemical Intermediates High-performance intermediates and actives for global agriculture leaders covering crop protection and crop nutrition solutions.
• Nutrition & Food Ingredients Vitamins (including Vitamin B3 / Niacinamide), premixes, and mineral complexes for food fortification and nutritional supplementation worldwide; supplemented by Remidex acquisition in 2026.
• Industrial Specialty Chemicals Specialty intermediates and antimicrobials for diverse industrial applications.
• Cosmetics, Flavour & Fragrance Ingredients Aroma chemicals and specialty ingredients for beauty, personal care and fine fragrance applications.
• Semiconductor Chemicals High-purity specialty chemicals for advanced chip manufacturing processes.
• Pyridine & Derivatives Leading global producer of Pyridine and derivatives used in agrochemical and pharmaceutical applications.
• Vitamin B3 (Niacinamide) Major producer of Vitamin B3 / Niacinamide for nutrition and pharmaceutical applications.
• Bio-based Chemicals Bio-based chemicals including Bio Pyridine (81% bio content), Bio Acetic Acid (98% bio content), and Bio Niacinamide (67% bio content) for sustainable chemistry solutions.
• R&D Services Research and development services across three R&D centres (Greater Noida, Gajraula, Bharuch) with 150 scientists including 30 PhDs and DSIR-recognised facility, supporting custom synthesis and process development.

Quantifiable outcome

• Q4 FY26 revenue grew 12% YoY to ₹1,179 crore; Full year FY26 revenue ₹4,388 crore (5% growth)
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• DPIIT / Start-up IndiacoreStrategic or Co-development Partner · 23 December 2025Jubilant Bhartia Foundation, the social arm of Jubilant Bhartia group, is implementing the Bharat Startup Grand Challenge – Fortify to Scale initiative in collaboration with DPIIT's Start-up India. The program accelerates nutrition-focused startups with support from IIMA Ventures, offering technical guidance, laboratories, manufacturing facilities, mentorship, market linkages, and investment capital.
• IIMA VenturescoreStrategic or Co-development PartnerStrategic partner providing support for the Bharat Startup Grand Challenge – Fortify to Scale incubation program, offering investment capital and startup ecosystem support alongside Jubilant Bhartia Foundation.
• Jubilant Bhartia FoundationcoreStrategic or Co-development PartnerSocial wing of Jubilant Bhartia group established in 2007, implementing CSR programs including Project Arogya (health), Project Muskaan (education), Nayee Disha (vocational training), and social business incubation. CSR expenditure budgeted at ₹634 lakhs for FY 2025-26.
• O2 RenewablesminorOthersRenewable electricity sourcing partnership through O2 Contract enabling 35% renewable energy usage with targeted renewable electricity implementation planned for manufacturing operations.

Scale indicators17 records

Recent moves6 records

Expansion highlights8 records

Broad incumbents

• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with significant API and intermediates production. Broader incumbent presence in APIs/formulations but with overlapping intermediates and chemistry platforms relevant to Jubilant Ingrevia's pharma business.
• Lonza Group: Global CDMO leader for pharma and biotech. Comparable CDMO service model and regulatory depth; serves as the global benchmark for where Jubilant Ingrevia's CDMO business is targeted.
• BASF: Global specialty and agricultural chemicals incumbent. Competitor across multiple Jubilant Ingrevia chemistries (Pyridine, vitamins, agro intermediates) as part of a broader portfolio.
• Tata Chemicals: Large Indian chemicals conglomerate with inorganic and specialty chemicals operations. Broader incumbent in Indian chemicals with related nutrition and specialty chemistries.

Direct peers

• PI Industries: Indian agrochemical CDMO leader with multinational innovator customers. Directly comparable on agrochem CDMO contract model and high-margin contract manufacturing revenue.
• SRF Limited: Indian diversified specialty chemicals and fluorochemicals manufacturer with CDMO capabilities for pharma and agro. Overlapping chemistry platforms, packaging films and specialty intermediates footprint.
• Laurus Labs: Indian pharma CDMO and API manufacturer with growing specialty ingredients exposure. Comparable CDMO contract structure and API intermediates business serving global pharma customers.
• Divi's Laboratories: India-headquartered API and CDMO manufacturer serving global pharmaceutical customers. Most directly comparable Indian peer with a similar API + custom synthesis model, pharma end-market focus and export-heavy revenue mix.
• Vinati Organics: Indian specialty chemicals company with global leadership in specialty monomers (IBB, ATBS). Comparable single-product/leadership-molecule specialty chemicals business model with pharma and industrial customers.

Regional players

• Coromandel International: Indian agro inputs manufacturer with crop protection and specialty nutrients. Overlaps with Jubilant Ingrevia's agrochemical and nutrition ingredients footprint from an Indian primary market perspective.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Ingrevia

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jubilant Ingrevia